Cell and Gene Therapy Manufacturing Services Market Report 2022: Rising Pharmaceutical R&D Investment Drives Growth – ResearchAndMarkets.com

0

DUBLIN–(BUSINESS WIRE)–The report “Analysis of Cell and Gene Therapy Manufacturing Services Market by Type, Indication, Application, End User and Region – Global Forecast to 2029” has been added to from ResearchAndMarkets.com offer.

The cell and gene therapy manufacturing services market size is estimated at USD 8.4 billion in 2021 and is expected to witness a CAGR of 14.56% during the forecast period 2022-2029. The high rate of cancer and other target diseases, increased investments in pharmaceutical R&D, investments in advanced technologies by CDMOs and the increase in partnerships and contracts between pharmaceutical companies and CDMOs are some of the -one of the major drivers of market growth.

However, increasing operational costs of manufacturing cell and gene therapies are expected to restrain the market growth.

By type

Based on type, the market is divided into gene therapy and cell therapy. In 2021, the cell therapy segment accounted for the highest revenue share due to the development of new technologies and product innovations that enabled a variety of cells, including mesenchymal stem cells, dendritic cells and T cells, hematopoietic stem cells (HSC), natural killer cells, to treat illnesses and diseases.

By indication

Based on the indication, the market is divided into central nervous system disorders, ophthalmological diseases, cardiovascular diseases, infectious diseases, orthopedic diseases, oncological diseases and others. In 2021, the infectious disease segment accounted for the largest share of revenue due to the expansion of cell therapy clinical trials due to the increase in the prevalence of infectious diseases.

By request

Based on application, the market is divided into commercial manufacturing and clinical manufacturing. In 2021, the clinical manufacturing segment accounted for the largest share of revenue due to the growing number of gene therapy clinical trials and the ever-expanding global pipeline of cell and gene therapies.

Per end user

On the basis of end-user, the market is categorized into academic and research institutes and pharmaceutical and biotechnology companies. In 2021, the academic and research institutes segment accounted for the highest share due to increased government research funding and increased spending in the life science R&D sector.

Regional markets

In 2021, the North America region accounted for the highest revenue in the cell and gene therapy manufacturing services market and is expected to maintain its dominance over the forecast period. This is attributed to the rising prevalence of cancer and growing cancer and stem cell research effort, and large investments in biopharmaceutical research and development are fueling the growth of the market. Also, increasing investment in pharmaceutical research and development is accelerating the expansion of the regional market.

Segmentation: Cell and Gene Therapy Manufacturing Services Market Report 2021-2029

By type (revenue, billion USD)

  • Genetical therapy

  • Cell therapy

By indication (turnover, billion USD)

  • Central nervous system disorders

  • Ophthalmological diseases

  • Cardiovascular illnesses

  • Infectious diseases

  • Orthopedic diseases

  • Oncological diseases

  • Others

By Application (Revenue, Billion USD)

  • Commercial manufacturing

  • Clinical manufacturing

Per End User (Revenue, Billion USD)

  • Academic and research institutes

  • Pharmaceutical and biotechnology companies

By region (revenue, billion USD)

North America

Europe

  • Germany

  • France

  • UK

  • Spain

  • Italy

  • The rest of Europe

Asia Pacific

  • China

  • Japan

  • India

  • Australia

  • South Korea

  • Rest of APAC

Latin America

  • Brazil

  • Mexico

  • Argentina

  • Rest of LATAM

Middle East and Africa

  • South Africa

  • GCC

  • Rest of MEA

Main topics covered:

1. Research methodology

2. Introduction: Cell and Gene Therapy Manufacturing Services

3. Executive Summary

4. Market dynamics

5. Analysis of the market environment

6. COVID-19 Impact Analysis: Cell and Gene Therapy Manufacturing Services Market

7. Market Analysis by Type

8. Market analysis by indication

9. Market Analysis by Application

10. Market Analysis by End User

11. Regional Market Analysis

12. North America Cell and Gene Therapy Manufacturing Services Market

13. Europe Market for Cell and Gene Therapy Manufacturing Services

14. Asia-Pacific Cell and Gene Therapy Manufacturing Services Market

15. Latin America Cell and Gene Therapy Manufacturing Services Market

16. MEA Cell and Gene Therapy Manufacturing Services Market

17. Competitor Analysis

18. Company Profiles

19. Conclusion and Recommendations

Companies cited

  • Thermo Fisher Scientific Inc. (USA)

  • Merck KGaA (Germany)

  • Charles River Laboratories (USA)

  • Lonza (Switzerland)

  • Catalent Inc. (USA)

  • WuXi AppTec (China)

  • Takara Bio Inc. (Japan)

  • NIKON CORPORATION (Japan)

  • FUJIFILM Holdings Corporation (Japan)

  • F. Hoffmann-La Roche SA (Switzerland)

  • Oxford Biomedica plc (UK)

  • Cell and Gene Therapy Catapult (UK)

  • The Discovery Labs LLC (USA)

  • RoslinCT (Scotland)

  • JRS PHARMA (Germany)

  • FinVector (Finland)

  • ABL Inc. (USA)

  • Resilience (USA)

  • BioCentriq (USA)

  • Porton Biopharma Limited (England)

  • elyn Biosciences (USA)

  • Commercialization of living therapies (Canada)

  • Vibalogics (USA)

  • Anemocyte Srl (Italy)

  • ElevateBio (USA).

For more information on this report, visit https://www.researchandmarkets.com/r/tflydy

Share.

Comments are closed.